National Stock Numbers Assigned to Critical Medical Countermeasures for the Warfighter
Posted by: Press Release |
Feb 11, 2020 |
JPM CBRN Medical facilitated standardization and assignment of National Stock Numbers to promote Joint Force readiness.FORT DETRICK, Md.
– The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM CBRN Medical) played a critical role in facilitating the assignment of National Stock Numbers (NSNs) to four medical countermeasures (MCMs) – developed under partnerships between manufacturers, the JPM CBRN Medical, and other U.S. government agencies – that protect our nation’s service members. NSNs are an essential part of the national logistics supply chain used in managing, moving, storing, and disposing of material. Assigning NSNs is a step forward in delivering these products to deployed forces, allowing the MCMs to be prepositioned in strategic locations around the globe and ensuring timely access to the products in regions where warfighters encounter unique threats.
The four products include:
• JYNNEOS™ smallpox vaccine (NSN 6505-01-684-4091)
• Tecovirimat (TPOXX®) smallpox treatment (NSN 6505-01-684-9538)
• Heptavalent Botulism Anti-Toxin (HBAT®) (NSN 6505-01-684-9483)
• EVZIO® naloxone autoinjector (NSN 6505-01-684-9014)
The JPM CBRN Medical sponsored the application for standardization and assignment of the NSN for JYNNEOS™, a U.S. Food and Drug Administration (FDA)-approved vaccine created by Bavarian Nordic and intended to prevent smallpox in adults 18 years of age and older determined to be at high-risk for infection. The JYNNEOS™ vaccine was developed as an alternative to the current U.S.-licensed replicating smallpox vaccine, ACAM2000, which cannot be used by certain populations, including people with atopic dermatitis and HIV. JYNNEOS™ is also currently the only FDA-approved vaccine for the prevention of monkeypox disease, able to be given to people with weakened immune systems. Assigning an NSN allows for future pre-positioning of the vaccine in locations where monkeypox infection of U.S. warfighters is possible.
Approved by the FDA in July 2018, SIGA Technologies, Inc.’s TPOXX® was the first drug with an indication for treatment of smallpox. Though the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that smallpox could be used as a bioweapon. The pre-positioning of TPOXX® will enable the DOD to address pox virus threats in areas where service members may be susceptible.Both JYNNEOS™ and TPOXX® enable the DOD to safely protect a wider range of warfighters against orthopox viruses such as smallpox and monkeypox.
Very rarely, botulism toxin events occur within the U.S. When they do, heptavalent botulism antitoxin (HBAT®) can be used to counter the toxin. While the JPM CBRN Medical considers HBAT® to be a MCM for a bio warfare agent, the product can be used to treat both sporadic naturally-occurring botulism toxin poisonings and intentional exposure. Manufactured by Emergent BioSolutions, Inc., HBAT® is the only product available for treating botulism in adults.
The JPM CBRN Medical has standardized kaléo, Inc.’s EVZIO® naloxone autoinjector (NAI) for inclusion into the Chemical Warfare Casualty Treatment Set. FDA-approved EVZIO® rapidly delivers a single 2 mg dose of the drug naloxone via a hand-held autoinjector in the event of an opioid overdose. While the 2 mg EVIZO® is now available for general use, the Rapid Opioid Countermeasure System (ROCS) program within the JPM CBRN Medical is currently developing a 10 mg NAI, under an agreement with kaléo, Inc., to treat the effects of highly-potent opioids and potentially reduce the number of 2 mg NAI required for treatment.About the JPM CBRN Medical: The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability. About the JPEO-CBRND: The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense is the Joint Service’s lead for development, acquisition, fielding and life-cycle support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures. As an effective acquisition program, the JPEO-CBRND puts capable and supportable systems in the hands of the service members and first responders, when and where it is needed, at an affordable price. Our vision is a resilient Joint Force, enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment, championed by innovative and state-of-the-art solutions